A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F. Liu, Ursula A. Matulonis, Robert M. Wenham et al.|Gynecologic Oncology|2024Cited by 11